AstraZenecaWainua's failed final trial was never expected to have a major financial impact on the company.
Most analysts estimate that the failure of the trial erased only 2% to 4% of their valuation models. However, the stock lost about twice as much in a single session, suggesting that the market reaction reflected more than just the loss of a drug, which was intended to treat a rare heart disease.
The disconnection has diverted attention from Wainua itself to something harder to measure: whether the valuation premium investors have long assigned to one of Europe's most respected drug pipelines is justified.
For years, AstraZeneca has been among the richest valuations among European big pharma companies, based on the assumption that management consistently conducts successful late-stage clinical trials in oncology, rare diseases and specialty drugs, and replenishes its pipeline with new blockbuster drugs.
Under the 14-year reign of CEO Pascal Soriot, AstraZeneca has developed a reputation as a pharmaceutical powerhouse that rarely publishes negative trial results.
Wainua was not expected to become one of AstraZeneca's most important products. Rather, the surprise lay in the failure of a program that many investors believed had a high probability of success.
Most analysts say the disappointment does not undermine AstraZeneca's long-term growth story, but it may have raised the bar to prove it.
The problem goes beyond the additional revenue Wainua would have added to AstraZeneca's revenue, as it dents the company's credibility, Jefferies analysts wrote in a note to clients on Thursday.
“This was meant to be a success, which made the complete failure surprising.”
Bigger than a drug
The financial impact of Wainua's failure as a treatment for ATTR cardiomyopathy, a rare and life-threatening heart disease, appears relatively modest.
Citi estimates the net present value impact at approximately 3%. Jefferies estimates around 2%, and Leerink Partners' reduction in price target implied a similarly limited impact. Bank of America described the impact on sales as “mid-single digits,” while Morningstar said Wainua's lower sales estimates do not significantly change its valuation.
Those estimates contrast with the market's reaction when shares fell 6.2% in Thursday's session, marking the stock's worst day in more than two years, and fell an additional 3% on Friday.
An AstraZeneca spokesperson declined to comment further on the share price reaction.
Rather than simply removing some of Wainua's sales from their models, investors may be reevaluating the confidence they place in AstraZeneca's broader portfolio and execution.
Dan Coatsworth, head of markets at AJ Bell, noted that AstraZeneca has had many more hits than misses recently, creating high expectations for success.
“AstraZeneca has bold plans to reach $80 billion in sales by 2030, and investors will now question whether this goal is credible,” Coatsworth said in emailed comments.
Jefferies said the failed test does not threaten the administration's 2030 ambition, while Citi continues to hope the company can exceed that goal.
Leerink noted that after speaking with management, removing Wainua for ATTR cardiomyopathy reduces the headroom above the company-provided consensus from about $82.7 billion to about $80.8 billion, reflecting Wainua's $1.9 billion in 2030 revenue.
Morningstar left its fair value estimate unchanged, saying the setback “does not change our view of its late-stage drug development capabilities,” while noting that AstraZeneca's oncology franchise, rare disease business and broader portfolio remain intact.
Both Goldman Sachs and Bank of America stressed that investors had not seriously considered the possibility that the trial would fail, given the favorable precedent of Alnylam Rival drug Amvuttra that works similarly.
An increasingly smaller margin of error?
The failed study also comes at an important time for AstraZeneca.
Several of the company's largest pipeline catalysts, including the AVANZAR trial for lung cancer, SERENA-4 for breast cancer and cliramitug also for ATTR cardiomyopathy, are expected to report data in the coming months, meaning investors' attention is now focused on fewer high-profile readouts.
AstraZeneca shares listed in London over the last 12 months.
“All eyes on ADVANCE,” Jefferies wrote, describing it as the next big catalyst that will likely determine sentiment. The reading is expected in July or August.
Leerink suggested the setback puts even more focus on the remaining “binary events” expected later this year.
Most analysts still recommend buying shares. Citi reiterated AstraZeneca as its top European pharma pick, Bank of America reiterated its Buy rating, and Jefferies argued that investors should “buy the dip.”
